MedTrace Logo

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

NCT00066196 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2008-01-15

No results posted yet for this study

Summary

The primary objectives of this study are:

* To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma.
* To determine the safety of MEDI-522 ± DTIC in this patient population.

Conditions

  • Melanoma
  • Malignant Metastatic Melanoma

Interventions

BIOLOGICAL

MEDI--522

IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.

BIOLOGICAL

Integrin + Dacarbazine

supplied in other formulations

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Luz Hammershaimb, M.D. · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2007-04-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00066196 on ClinicalTrials.gov